Biomics

The analysis of the association of polymorphic markers of genes of nuclear factor κappa B (rs147169338, rs45581936) and the family of interleukin-1 (rs1143634, rs2287047, VNTR IL1R1, Alu InDel Ya5NBC51) with a susceptibility to breast cancer. Revealed the presence of protective alleles at polymorphic markers of genes subunits of nuclear factor-κb in all studied individuals, indicating a normal functioning of this transcription factor. An increase in the frequency of allele IL1RN*genotype II and II/II in the group of breast cancer patients compared with healthy, indicates the association of this variant of the polymorphic marker with the development of breast cancer. This polymorphism influenced the level of gene expression and as a consequence, the concentration of interleukin-1 in the intercellular space, which increases the proliferation of cells and can stimulate the cancer patients develop metastases.

breast cancer, nuclear factor κappa B, NF-kb1, NF-кb2, interleukin 1,IL-1β, IL1RN, IL1RI, IL1RAP

1. Бережная Н.М. Роль клеток системы иммунитета в микроокружении опухоли. Взаимодействие клеток системы иммунитета с другими компонентами микроокружения // Онкология. 2009. Т. 11. №2. С. 86–93.
2. Герштейн, Е. С.Клинические исследования компонентов NF-kB-сигнального пути в злокачественных опухолях молочной железы// Лабораторная служба. - 2013. - № 1. - С. 39-45.
3. Громова А. Ю. Полиморфизм генов семейства IL-1 человека / А. Ю. Громова, А. С. Симбирцев // Цитокины и воспаление. –2005. – Т. 4. – № 2. – С. 3–12.
4. МаянскийА.Н., Маянский Н.А., Заславская М.И. Нуклеарный фактор-κB и воспаление. Цитокины и воспаление. 2007. Т. 6, № 2. С. 3-9.
5. Симбирцев А.С., Конусова В.Г., Кетлинский С.А. Иммуноцитохимический анализ продукции интерлейкина-1b моноцитами человека // Бюлл. экспер. биол. мед.- 1991.- № 9.- С. 278-280.
6. Соснина А.В., Великая Н.В., Аутеншлюс А.И. Роль цитокинов в патогенезе злокачественных новообразований / Новосибирск: Вектор-Бест, 2013. – 80 с.
7. Bergholdt R., Larsen Z.M., Andersen N.A. et al. Characterization of new polymorphisms in the 5 UTR of the human interleukin-1 receptor type 1 (IL1R1) gene: linkage to type 1 diabetes and correlation to IL-1RI plasma level // Genes and immunity. 2000. V.1. P. 495–500.
8. Chen W.-C., Wu H.-C., Chen H.-Y., et al. Interleukin-1β gene and receptor antagonist gene polymorphisms in patients with calcium oxalate stones // Urol Res. 2001. V. 29. P. 321–324.
9. Ferrero-Miliani L, Nielsen OH, Andersen PS, Girardin SE.Chronic inflammation: Importance of NOD2 and NALP3 in interleukin-1beta generation. Clin Exp Immunol 2007; 147:227–35.
10. Gantsev S.K., Gorbunova V.Y., Galikeeva G.F., Vorobyeva E.V., Vasilyeva E.M., Rustamhanov R.A. Molecular Genetic Study of the Allelic State of the Cell Cycle Genes (TP53, BRCA1) and Features of the Regulation of the Cytokine Cascade in Breast Cancer // Journal of Cancer Research Updates, 2013. Vol.2. P.211-219.
11. Greenfeder S., Nunes G., Kwee L., Labow M., Chizzonite R. and Ju G. (1995) Molecular cloning and characterization of a second subunit of the interleukin 1 receptor complex. J. Biol. Chem. 270, 13747-
12. Hurme M., Santtila S. IL-1 receptor antagonist (IL-1RA) plasma levels are co-ordinately regulated by both IL-1RA and IL-1β genes // Eur J Immunol. 1998. V. 28. P. 2598–2602.
13. Lewis A. M. Interleukin-1 and cancer progression: the emerging role of interleukin-1 receptor antagonist as a novel therapeutic agent in cancer treatment / A.M. Lewis, S. Varghese, H. Xu, H.R. Alexander // J. Transl. Med. – 2006. – Vol. 4. – P. 48.
14. Mathew C.C. The isolation of high molecular weight eukaryotic DNA // Methods in Molecular Biology / Ed. Walker J.M.N. Human Press. 1984. V. 2. P. 31–34.
15. Watkins LR, Milligan ED, Maier SF. Glial activation: a driving force for pathological pain // Trends in Neuroscience.2001;24:450–455.